MAR 2 3 7004 SA

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 3

Application Number	10/634,682		
Filing Date	08/05/2003		
First Named Inventor	Bart De Corte		
Group Art Unit	1614		
Examiner Name			
Attorney Docket Number	JAB 1425 Con 1		

U.S. PATENT DOCUMENTS

		U.S. Patent Document				
Examiner Intiels	Cite No.1	Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Misc.
M	1	4,659,383		Hubele et al.	04-21-1987	Priority to same application as EP 0945443 listed below.
V	2	5,691,364		Buclonan et al.	11-25-1997	
	3	6,048,866		Hutchings et al.	04-11-2000	
8	4	6,093,716		Davis et al.	07-25-2000	
N	5	6,197,779	B1	Andries et al	03-06-2001	

FOREIGN PATENT DOCUMENTS

		Foreign	Patent Docume	nt	Name of Patentee or Of Cited Document			
Examiner Initials	Cite No. ¹	Office ³	Number K	indCode ⁵	Applicant of Cited Document	mm-dd-yyyy	Translation	T ⁰
B	6	ΕÞ	0945443	A1	JANSSEN PHARMACEUTICA, NV	09-29-1999	No	
M	7	wo	98/41512	A1	CELLTECH THERAPEUTICS, LTD	09-24-1998	No	
M	8	EP	0945442	A1	JANSSEN PHARMACEUTICA, NV	09-29-1999	No	
M	9	wo	95/10506	A1	DU PONT MERCK PHARMACEUTICAL	04-20-1995	No	
M	10	EP	0371139	B1	MIYASAKA, Tadashi	10-12-1994	No	
M.	11	₽	0135472	A2	CIBA-GEIGY A.G.	03-27-1985	No	
2	12	₽	0 588 762	A1	CIBA-GEIGY A.G.	08-23-1993	Yes	
DA	13	£	0 135 472	A2	CIBA-GEIGY A.G.	07-19-1984	English Abstract	
V	14	ΕP	0834,507	A1	JANSSEN PHARMACEUTICA, NV	04-08-1998	No	

Examiner 1 1 1 1 1	Date	OLIDIM.	
Signature // Dalasura	 Considered	0111104	

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant. • 1 Applicant's unique citation designation number (optional). • See Kinds Codes of USPTO Patent Documents at www.uspi...gov or MPEP 901.04. • Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). • For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. • Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. • Applicant is to place a check mark here if English languaged Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Petent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

MR 2 3 MM 2 3 MM

PTO/SB/08A (08-00)
Approved for use through 10/31/2002, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Papermont Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 2 of 3

a collection of information unless it displays a	velid OMB control number.
Application Number	10/634,682
Filing Date	08/05/2003
First Named Inventor	Bart De Corte
Group Art Unit	1614
Examiner Name	
Attorney Docket Number	JAB 1425 Con 1

		OTHER - NON PATENT LITERATURE DOCUMENTS					
		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s),					
Examiner's	Cite	Translation	T²				
initials*	No.1						
	15	ARNOLD, et al., Inhibitor conformational flexibility and positional variation are important for					
1M		activity against drug-resistant virus: crystal structures of highly potent non-nucleoside		!			
Λ./	1	inhibitors of HIV-1 reverse transcriptase, 21th European Crystallographic Meeting, Durban,		1			
	i	South Africa, 24-29, Aug. 2003.		1			
V	16	ARNOLD, Conformational Flexibility of DAPYs: activity against resistant HIV, Aug. 2003.		<u> </u>			
M	17	BUAGOVIC, et al., Validation of a Model for the Complex of HIV-1 Reverse Transcriptase	•				
V	i '	with Nonnucetoside Inhibitor TMC125, J. AM. CHEM. SOC. 2003, Vol. 125, pp. 6016-6017.		<u> </u>			
	18	CLARK, Inhibitor conformational flexibility and positional variation are important for activity		Τ			
M		against drug-resistant virus: crystal structures of highly potent non-nucleoside inhibitors of		1			
10	1	HIV-1 reverse transcriptase, 21th European Crystallographic Meeting, Durban, S. Africa, 24-		i			
1	l	29, Aug. 2003.		L			
IM	19	DAS, et al., Could multiple modes of binding of a potent NNRTI TMC125-R165335 explain		1			
M		its potency against common drug-resistant mutants?, CROI, Boston, Feb. 2003		L			
DM	20	M-P de BETHUNE, TMC 125 resistance profiles, Resistance, Mexico, June 2003					
	21	FURUKAWA, et al., Syntheses of Compounds related to Guanidine and their Inhibitory					
5		Action on Growth of HeLa Cells, Chem. Pharm. Bull. 9 (11), 914-921 (1951)					
	22	GAZZARD, et al., TMC125, A Next-Generation NNRTI, Demonstrates High Potency After 7					
M	ļ	Days Therapy in Treatment-Experienced HIV-1 Infected Individuals with Phenotypic NNRTI		l			
,	1	, CROI, Seattle, Feb. 2002.		<u> </u>			
2. A	23	GAZZARD, et al., An open-label essessment of TMC 125 - a new, next-generation NNRTI,					
(\mathcal{V})	1	for 7 days in HIV-1 infected individuals with NNRTI resistance, AIDS 2003, Vol. 17, pp. 49-		ľ			
0.7		54.		<u> </u>			
PLA.	24	GAZZARD, et al., TMC125, a Next Generation NNRTI, Demonstrates High Potency After 7	,				
\mathcal{M}	İ	Days Therapy in Treatment-Experienced HIV-1 Infected Individuals with Phenotypic NNRTI-					
	L'	Resistance, XIV International AIDS Conference, July 7-11, 2003, Barcelona, Spain		<u> </u>			
M	25	GAZZARD, TMC 125 C207 study treatment-experienced, CROI Seattle, Feb. 2002					
W	26	GAZZARD, 7 day treatment-experienced, WAC Barcelona, Jul. 2002					
- (1A	27	GRUZDEV, et al., A Randomized, double-blind, placebo-controlled trial of TMC125 as 7-day	: No				
(M)		monotherapy in antiretroviral naive HIV-1 infected subjects, AIDS 2009, VOL 17, pp. 2487-		1			
	l	2494.		l			
100	28	GULICK, New Antiretroviral Drugs, Clinical Microbiology and Infectious Diseases, CMI, 9,		T -			
W		(3) pp. 186-193 (March, 2003)		[
VV	29	LANGE, TMC 125 decay rate vs ERA, CRO! Seattle, Feb. 2002					
M	30	LEWI, Potency & multiple binding modes of TMC 125, CROI Boston, Feb. 2003		Τ			
Ł.A	31	LUDOVICI, et al., Evolution of Anti-HIV Drug Candidates. Part 3: Diarylpyrimidine (DAPY)		T			
W	'	Analogues, Bioorganic & Medical Chemistry Letters 11, 2001, pp. 2235-2239.		1			
٠M	32	SANKATSING, et al., TMC 125 Monotherapy for One Week Results in a Similar Initial Rate		1			
M		of Decline of HIV-1 RNA as Therapy With a 5-Drug Regimen, CROI, Seattle, Feb., 2002.		ł			
LIA	33	SANKATSING, et al., TMC125 exerts similar initial antiviral potency as a five-drug, triple		 			
(M)		cless antiretroviral regimen, AIDS 2003, Vol. 17, pp. 2623-2627.		[
		The state of the s		 			

Examiner Signature	Balasawa	meurch Date Considere	8176	04

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 2 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4. For Japanese patent documents, the Indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 3°C FR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form should be earl to the Chief Information Officer, U.S. Petent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Palant and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Under the Paperwork Reduction Act of 1995, no persons are required to respond to

(use as many sheets as recessary)
Sheet 3 of 3

Application Number	10/634,682		
Filing Date	08/05/2003		
First Named Inventor	Bart De Corte		
Group Art Unit	1614		
Examiner Name			
Attorney Docket Number	JAB 1425 Con 1		

		OTHER - NON PATENT LITERATURE DOCUMENTS		
Examiner's Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Translation	T²
1/2	34	TMC 125 for 7 days in HIV-1+ individuals with NNRT1 resistance (TMC 125- C207), AIDS, 17 (18): F49-54, Dec. 5, 2003		
W)	35	TMC 125 as 7d monotherapy in ARV-naïve subjects (TMC 125-C208), AIDS, 17(17): 2487-2494, Nov. 21, 2003.		
M	36	TMC 125 similar potency to 5-drug, 3-class regimen, AIDS, 17(18): 2623-2627 Dec. 5, 2003		
W)	37	UDIER-BLAGOVIĆ, et al., Validation of a Model for the Complex of HIV-1 Reverse Transcriptase with Nonnucleoside Inhibitor TMC125,J. AM CHEM. SOC. 2003, Vol. 125, pp. 6016-6017.		
W	38	VINGERHOETS, et al., Antiviral activity of TMC125, a potent next-generation NNRTI, against > 5000 recombinant clinical isolates exhibiting a wide range of (NNRTI) resistance, XIIth International HIV Drug Resistance Workshop, June 10-14, 2003, Mexico.		
M	39	VINGERHOETS, et al., Antiviral activity of TMC Against a Panel of Site-Directed Mutants Encompassing Mutations Observed In Vitro and In Vivo, Poster No. 621, Presented at the Xith Conference on Retrovirus and Opportunistic Infections, Feb. 8-11, 2004, San Francisco, CA USA		
W	40	VINGERHOETS, Antiviral activity TMC 125 SDM CROI, San Francisco, Feb. 2004.	No	
W	41	VINGERHOETS, et al., Characterization of Resistance Before and After Short-Term Therapy with TMC125 in Patients with Documented NNRTI Resistance, Xlith International HIV Drug Resistance Workshop, June 10-14, 2003, Mexico		
M	42	VINGERHOETS, Resistance before/after therapy - TMC 125C207, XII Resistance Mexico, June 2003.		
m	43	VINGERHOETS, Resistance profile clinical isolates TMC 125, XII Resistance, June 2003, Mexico		
W	44	VINGERHOETS, TMC-125-C207 resistance analysis, Resistance, June 2003, Mexico		
W	45	UDIER-BLAGOVIĆ, et al., Validation of a Model for the Complex of HIV-1 Reverse Transcriptase with Nonnucleoside Inhibitor TMC125, J. AM< CHEM. SOC. 2003, Vol. 125, pp. 6016-6017.	ವರ್ಧಿಸ	
			 	
			ļ	

Examiner Signature	11.Ba	lasur	menter	Date Considered	8/17/04

"EXAMINER: Initial if reference considered, whether or not catation is in conformance with MPEP 609. Draw tine through citation if not in conformance and not considered, include copy of this form with ned communication to applicant. 1 Applicant's unique citation designation number (optional), 2 See Kinds Codes of USPTO Pattent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4. For Japanese patent documents, the indication of the year of the retin of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 4 Applicant is to place a check mark here if English language Translation is attached.

This coffection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to fite (and by the USPTO to process) an application. Confidentiatity is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.